HEV Capsid as Multivalent Immunogens or for Drug Delivery Systems

Tech ID: 11173 / UC Case 2008-639-0


Peptide fusion with or encapsulation of nucleic acid by the truncated capsid protein of the hepatitis E virus (HEV) can cause specific antigenic responses in the host.

Full Description

A portion of the hepatitis E virus (HEV), the truncated capsid protein, is able to self-assemble into a virus like particle (VLP) that contains no HEV genomic RNA. The VLP can be modified by deletions or modifications to the truncated capsid protein and by itself stimulates response to HEV.

Researchers at the University of California, Davis have discovered that fusion of the HEV capsid protein with a heterologous peptide can cause specific antigenic responses in the host. Furthermore, the VLP can also encapsulate nucleic acid, permitting another method for stimulating antigenic responses in the host. Specific lysis by CTL effect in response to HIV epitopes was evaluated by spleen, mesenteric lymph nodes and Peyer’s patch cells from immunized animals. Synergistic effects are possible when the capsid is fused to a peptide while also encapsulating a nucleic acid or other drug.


  • Oral immunization with this capsule induces intestinal and systemic immune responses
  • Delivery of foreign antigenic epitopes to cause antigenic responses
  • Delivery system through encapsulation of nucleic acid and antivirals
  • Further investigation of HEV/HEV capsid structure
  • Investigation of HEV capsid role in zoonotic infections
  • Strategies are in place to prevent existing or developing immunity
  • Prophylactic and therapeutic treatment


  • Targeting on mucosal surfaces to be stimulated, as one mucosal surface by an antigen induces mucosal immunity both on the stimulated surface and on the distant ones
  • Fusion of heterologous peptides to the capsid permits specific antigenic stimulation in the host
  • Multiple deliveries of the VLP-drug, including oral delivery, are possible because of the interaction of VLP with the mucosal layer
  • The delivery of the encapsulated DNA vaccines can also be achieved by non-invasive routes
  • Targeted delivery and specific antigenic stimulation that would otherwise be difficult to achieve

Related Materials

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 9,637,524 05/02/2017 2008-639
United States Of America Issued Patent 8,906,862 12/09/2014 2008-639
United States Of America Issued Patent 8,906,863 12/09/2014 2008-639


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Cheng, R. Holland
  • Xing, Li

Other Information


hepatitis E virus, HEV, HEV capsid protein, antigenic response, virus like particle, VLP, heterologous peptide fusion

Categorized As